This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction

This study has been completed.
Information provided by (Responsible Party):
Royan Institute Identifier:
First received: July 19, 2010
Last updated: June 19, 2016
Last verified: July 2010

One of the important reasons for human dying is Ischemic heart disease (IHD). The most reason is coronary artery disease. Beside morbidity, IHD induce myocardial infarction and necrosis which due to congestive heart failure.

One therapeutic method is cellular cardiomyoplasty, which is to produce and substitute the cardiac cells with stem cell transplantation. Cell therapy is a potential therapeutic method to prevent ventricular remodeling after acute myocardial infarction. Human and animal studies have shown that stem cell trans plantation to myocardial infarcted zone can improve heart contractile function.

The aim of this study is to comparison the effects of BM-derived AC133 and MNC implantation in patients with myocardial infarction.

Condition Intervention Phase
Myocardial Infarction Biological: MNC Biological: AC 133 Biological: Control Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Autologous Bone Marrow Derived Ac 133+ and Mono Nuclear Cells In-patient With Acute Myocardial Infarction During Coronary Artery Bypass Grafting (CABG): A Randomized Phase III Clinical Trial

Resource links provided by NLM:

Further study details as provided by Royan Institute:

Primary Outcome Measures:
  • Left ventricular ejection fraction at rest, measured by gated SPECT [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Regional contractility in the AOI / Change in LV dimensions (left ventricular end systolic diameter [LVESD], left ventricular end diastolic diameter [LVEDD]) as assessed by echocardiography [ Time Frame: 6 months ]
  • changes in LVM index, LVEDV, LVESV [ Time Frame: 6 months ]

Enrollment: 90
Study Start Date: January 2008
Study Completion Date: July 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MNC implantation
Implantation of BM derived MNC
Biological: MNC
Implantation of BM derived MNC
Other Name: MNC injection
Experimental: AC 133 implantation
Implantation of BM derived AC 133
Biological: AC 133
Implantation of BM derived AC133
Other Name: AC133 injection
Placebo Comparator: Control
Injection of cell carrier
Biological: Control
Injection of cell carrier
Other Name: Placebo


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CABG candidate
  • At least 4 akinetic segments
  • First anterior heart attack within in 10 days to 3 month.
  • St elevation MI defined by: Post Acute MI LVEF less than 45% as assessed by echocardiography.
  • The target lesion had to be located in the left anterior descending (LAD) section.

Exclusion Criteria:

  • History of prior anterior myocardial infarction:
  • History of prior CABG
  • Poor echocardiography window.
  • Active infection or history of recurrent infection or positive test for syphilis (RPR), hepatitis B and C (HBSAg/ Anti HBc Anti - Hcv) HIV and HTLV-l
  • Documental terminal illness or malignancy.
  • Previous bone marrow transplant
  • Autoimmune disease (e. g Lupus, Multiple sclerosis)
  • Any contraindication for bone - marrow aspiration.
  • Positive pregnancy test (in women with child bearing potential)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01167751

Iran, Islamic Republic of
Royan Institute
Tehran, Iran, Islamic Republic of
Sponsors and Collaborators
Royan Institute
Study Chair: Hamid Gourabi, PhD Royan Institute
Principal Investigator: Hossein Baharvand, PhD Royan Institute
Principal Investigator: Mohammadhassan Nasseri, MD Baghiatollah
Study Director: Nasser Aghdami, MD, PhD Royan Institute
  More Information

Additional Information:
Responsible Party: Royan Institute Identifier: NCT01167751     History of Changes
Other Study ID Numbers: Royan-Heart-001
Study First Received: July 19, 2010
Last Updated: June 19, 2016

Keywords provided by Royan Institute:
Myocardial infarction
Bone marrow stem cells

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on August 21, 2017